Pinnacle Life Science, a Subsidiary of Aarti Drugs Ltd, Expands Further with UK MHRA GMP Compliance

Pinnacle Life Science, a Subsidiary of Aarti Drugs Ltd, yet again accomplished anor achievement on October 2, 2024, as y received UK Medicines and Healthcare Products Regulatory Agency (MHRA) Good Manufacturing Practice (GMP) Compliance Certificate. accreditation comes after a thorough audit, which was conducted in June 2024. This acquisition reflects Pinnacle’s dedication in producing pharmaceutical products that meet highest international quality and safety standards.
 

Pinnacle’s General Oral Solids facility in Bdi is a world-class manufacturing hub designed to meet and exceed global regulatory requirements. Prior to receiving UK MHRA certification, this facility h alrey earned approvals from or respected regulatory agencies, including PIC/s, MCAZ, Digemid-Peru, NDA , TFDA, and EFDA. plant is equipped with current Good Manufacturing Practice (cGMP) compliant equipment, automated production processes controlled via Programmable Logic Controllers (PLCs), and sophisticated software to maintain strict quality management systems (QMS) and laboratory activities. 
 

Pinnacle Life Science has consistently exceeded its benchmark in terms of its quality and compliance guidelines. By accomplishing certification, it is now all set to import its formulations with latest GMP Compliance Certificate to UK market. y have also now broened its access to or regulated markets that recognize UK standards, including Cana, Australia, New Zealand, and South Africa. With an exciting pipeline of over 20 molecules rey for commercialization across se regulated markets, Pinnacle is well-positioned to make a detrimental way forward in its international growth. Some products in pipeline include Sitagliptin range, Dapagliflozin and combinations, Empagliflozin and combinations, Apixaban, and Rivaroxaban.
 

“Our goal has always been clear and simple. We want to make quality, patient-centric medicines that can meet needs of market. Surely, we also want to expand in international market, and for that, my team and I are dedicated to deliver highest quality standards across our operations, starting from R&D to our quality assurance checks. We are just getting started with UK MHRA GMP Certificate; we have a lot more to achieve and accomplish”, said Vishwa Savla, Founder and Managing Director. 
 

Pinnacle Life Science has also received prestigious US FDA approval for its Oncology Facility in Bdi earlier this year. A top-notch structure quality policy and system have been implemented on all units of Pinnacle, preparing it to vance its position as a market leer by competing in worldwide pharmaceutical market.

About Pinnacle:

Pinnacle Life Science Pvt. Ltd, a subsidiary of Aarti Drugs Ltd, is an emerging global name in pharmaceutical industry. Aarti Drugs Ltd. has an annual turnover exceeding Rs. 5000 Cr specialising in bulk APIs and intermediates. This contributes to Pinnacle’s finished formulations and dosages, supported by two state-of--art cGMP-compliant manufacturing facilities in India. Spanning a 35-year legacy in healthcare and an annual production capacity of 3 billion tablets and 300 million capsules, company boasts a comprehensive portfolio of medications for acute and chronic ailments, including specialized areas such as Anti-Diabetic, Anti-Cancer, and Anti-Hypertensive treatments. company’s global presence is across North and Latin America, Europe, Africa, Asia, and beyond. company partners with over 250 clients worldwide, emphasizing collaborative growth through diverse business models such as licensing, co-development, contract manufacturing, and tech transfer.